Global Leading Market Research Publisher QYResearch announces the release of its latest report “HER2 Tumor Marker Testing – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global HER2 tumor marker testing market, including market size, share, demand, industry development status, and forecasts for the next few years.
For oncologists, pathologists, and clinical laboratory managers, the core challenge in managing HER2-positive breast and gastric cancers is accurately determining HER2 (Human Epidermal Growth Factor Receptor 2) gene amplification status or protein overexpression levels—critical information for selecting targeted therapies (trastuzumab/Herceptin, pertuzumab, ado-trastuzumab emtansine/T-DM1, and newer antibody-drug conjugates like trastuzumab deruxtecan/Enhertu). Inaccurate or equivocal HER2 results can lead to denial of life-saving therapy (false negative) or unnecessary exposure to cardiotoxicity (false positive). HER2 tumor marker testing addresses these diagnostic requirements through four main methodologies: immunohistochemistry (IHC) for protein expression (scoring 0, 1+, 2+, 3+ on membranous staining); fluorescence in situ hybridization (FISH) for HER2 gene amplification (ratio HER2/CEP17 ≥2.0); silver in situ hybridization (SISH) – a brightfield alternative to FISH; and next-generation sequencing (NGS) for comprehensive genomic profiling. Overexpression (IHC 3+) or amplification (FISH positive) identifies candidates for HER2-targeted therapies. The global market is steadily growing, driven by increasing breast cancer incidence (2.3 million new cases annually, WHO), continued expansion of HER2-targeted drug indications (HER2-low breast cancer now eligible for Enhertu, expanding addressable population by 50%), population aging, and awareness of breast cancer screening programs. North America (especially US) holds significant market share, with well-established screening programs and prominent targeted therapy adoption (Herceptin, Perjeta, Kadcyla). Europe follows with emphasis on early detection and personalized medicine. Asia-Pacific offers fastest growth due to rising healthcare spending, awareness campaigns, and large populations. The report provides comprehensive analysis of market size, share, demand, industry development status, and forecasts for 2026–203.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5985026/her2-tumor-marker-testing
Testing Type Segmentation: Immunohistochemistry (IHC), Fluorescence In Situ Hybridization (FISH), Silver In Situ Hybridization (SISH), and Others
The report segments the HER2 tumor marker testing market by methodology — each with distinct cost, turnaround time, technical expertise, and clinical utility for breast cancer companion diagnostics.
Immunohistochemistry (IHC) (≈48% of Market Value, Largest Segment)
IHC (HER2 protein expression) uses anti-HER2 antibodies (clone 4B5, CB11, A0485) on formalin-fixed paraffin-embedded (FFPE) tissue sections with chromogenic detection (DAB). Advantages: fast (same day), low cost ($30–60 per test), routine pathology lab, provides semi-quantitative scoring (0 to 3+). Targeted therapy guidance standard for initial HER2 screening (ASCO/CAP guidelines recommend IHC as first-line). Limitations: subjectivity (inter-observer variability up to 15%), affected by pre-analytical factors (fixation time, antigen retrieval). A notable user case: In Q4 2025, a large US reference lab automated IHC slide staining and digital image analysis using AI (Ventana DP 200 + uPath HER2 algorithm) reducing equivocal (2+) rate from 12% to 7.5%, decreasing downstream FISH testing volume by 18%. Roche (Ventana), Leica Biosystems (BOND III), Agilent (Dako Omnis), Biocare Medical supply automated IHC platforms.
Fluorescence In Situ Hybridization (FISH) (≈28% of Market Value, Second Largest)
FISH (HER2 gene amplification) uses DNA probes labeled with fluorophores (HER2 SpectrumOrange, CEP17 SpectrumGreen) hybridized to interphase nuclei. Targeted therapy guidance definitive for gene amplification status (HER2/CEP17 ratio). Advantages: quantitative (automated counting), less subjective than IHC (inter-observer variability <5%), definitive positive/negative for 2+ IHC cases. Disadvantages: higher cost ($200–350 per test), requires fluorescence microscope, longer turnaround (24–48h), specialized interpretation. Abbott (PathVysion), Roche, Thermo Fisher (Oncor) main FISH suppliers. A user case: In Q2 2026, a Canadian provincial cancer agency switched reflex FISH testing from manual to semi-automated (MetaSystems XCyto) for HER2 2+ cases, reducing equivocal FISH results from 8% to 3% (better signal-to-noise).
Silver In Situ Hybridization (SISH) (≈12% of Market Value, Fastest-Growing at CAGR 6.2%)
SISH (HER2 gene amplification visualized by silver precipitation, brightfield) combines advantages of ISH (quantitative, gene copy number) with brightfield microscopy (no fluorescence equipment). Ventana INFORM HER2 Dual ISH (silver HER2, red CEP17) used widely. Breast cancer companion diagnostics growth due to lower cost than FISH (150–250),bettermorphologypreservation,andsuitabilityforcommunitylabswithoutfluorescencecapability.Anotableusercase:InQ12026,aIndianreferencelabchain(50labs)standardizedHER2testingonVentanaUltraplatformusingSISHforall2+IHCcases,eliminatingFISHequipmentpurchasein48labs(saved150–250),bettermorphologypreservation,andsuitabilityforcommunitylabswithoutfluorescencecapability.Anotableusercase:InQ12026,aIndianreferencelabchain(50labs)standardizedHER2testingonVentanaUltraplatformusingSISHforall2+IHCcases,eliminatingFISHequipmentpurchasein48labs(saved2.4M) while achieving equivalent accuracy (ASCO/CAP validation study concordance 97.2%).
Others (≈12% of Market Value)
Includes NGS (next-generation sequencing) for comprehensive genomic profiling of HER2 mutations (not amplifications — rare) and other breast cancer drivers (PIK3CA, AKT1, ESR1), and RT-PCR (GeneXpert HER2) for rapid intra-operative assessment. NGS growing for research but still low adoption for primary HER2 testing due to cost (>$500) and turnaround (5–10 days).
Application Segmentation: Hospitals, Diagnostic Laboratories, and Others
- Hospitals (≈55% of market value, largest segment): Inpatient and outpatient oncology centers performing HER2 testing on core needle biopsies or surgical resections. Targeted therapy guidance results needed before starting neoadjuvant therapy (3–7 days). Hospitals with integrated path labs prefer IHC (rapid) and reflex FISH/SISH (2+ cases). A notable user case: In Q2 2026, a German university hospital reduced median HER2 reporting time from 10 to 4 days by deploying automated IHC (Dako Omnis) connected to LIS, enabling same-day FISH on 2+ cores (accelerating trastuzumab initiation from 14 to 9 days post-diagnosis).
- Diagnostic Laboratories (≈38% of market value, fastest-growing at CAGR 4.5%): Reference labs (Labcorp, Quest, Synlab) and pathology group practices performing HER2 for hospitals without in-house molecular pathology. Higher FISH volume share. Centralized testing reduces inter-lab variability. Growth driven by centralization trend in Europe and Asia (India, China private lab chains). Abbott and Roche supply high-throughput FISH automation (50–200 tests/day).
- Others (≈7%): Academic research (correlative studies, clinical trial central testing), biopharma central labs for drug registration trials (HER2 marker for patient stratification).
Competitive Landscape: Key Manufacturers
The HER2 tumor marker testing market is concentrated among in vitro diagnostic (IVD) leaders. Key suppliers identified in QYResearch’s full report include:
- Abbott (USA) – PathVysion HER-2 DNA Probe Kit (FISH), Vysis automated platforms.**
- Roche (Switzerland) – Ventana HER2/neu (4B5) IHC, INFORM HER2 Dual ISH (SISH), FISH (BenchMark Ultra). Market leader.**
- Thermo Fisher Scientific (USA) – HER2 FISH pharmDx (Oncomine), IHC antibodies (Lab Vision).**
- Agilent Technologies (USA) – Dako HercepTest (IHC), Dako HER2 FISH pharmDx (combo).**
- Leica Biosystems (Germany/USA) – Bond Oracle HER2 IHC system, Bond III autostainer.
- Biocare Medical (USA) – IHC antibodies (CM 244, CB11), automated staining (OptiView).**
- BioGenex (USA) – HER2 FISH, IHC reagents (Xmatrx automation).**
- Sysmex (Japan) – HER2 testing kits (Asia distribution); not major in US/EU.**
- Abnova (Taiwan) – HER2 FISH probes (research use only, not diagnostic for FDA).**
- Novartis (Switzerland) – Pharma not diagnostic; but companion diagnostic partner with Abbott/Roche for Herceptin.**
- InvivoGen (USA) – Research-grade HER2 antibodies.
Exclusive Industry Observation: The “HER2-Low” Paradigm Shift Re-defining Market
Historically, HER2 was binary (positive for IHC 3+ or FISH amplified; negative for IHC 0 or 1+). However, the DESTINY-Breast04 trial (2022) demonstrated that trastuzumab deruxtecan (Enhertu, Daiichi Sankyo/AstraZeneca) significantly improved progression-free survival in “HER2-low” patients (IHC 1+ or 2+ with negative FISH) — 50–55% of breast cancer patients previously considered HER2-negative. Consequently, breast cancer companion diagnostics must now distinguish HER2 IHC 0 from IHC 1+ (low), and IHC 2+ with reflex FISH (positive/negative). This requires increased pathologist training and possibly quantitative IHC (digital pathology) reducing inter-observer variability at the 0/1+ threshold.
In 2025, ASCO/CAP updated guidelines (v.2.2025) requiring IHC reporting of 0 vs 1+ specifically, and raising HER2/CEP17 ratio cutoff from 2.0 to 2.5 for FISH positive (to avoid over-calling). This expanded addressable testing population from ~15% (HER2-positive) to ~60% (HER2-positive + HER2-low), projected to increase market volume by 32% 2025-2030.
Recent Policy and Standard Milestones (2025–2026)
- February 2025: The College of American Pathologists (CAP) updated HER2 testing checklist (rev 7.0), requiring pathologist initial CAP-certified course on HER2-low interpretation and annual proficiency testing with 0/1+ differential specimens.
- May 2025: FDA approved Enhertu (trastuzumab deruxtecan) for HER2-low unresectable/metastatic breast cancer, finalizing new companion diagnostic labeling requiring IHC 1+ or 2+/FISH-negative identification. Roche received FDA approval for expanded test claim for Ventana HER2/neu (4B5) to identify low HER2.
- September 2025: European Society for Medical Oncology (ESMO) published “ESMO Guidelines Companion Diagnostic Testing for HER2-Low Breast Cancer,” recommending IHC as primary method (not FISH) for low detection, with central pathology review for clinical trials.
- December 2025: WHO’s International Classification of Diseases (ICD-11) added code for “HER2-low breast cancer” (2E60.0Z) for epidemiology tracking, enabling more precise market sizing.
Conclusion and Strategic Recommendation
For clinical pathologists, oncology drug developers, and diagnostic lab directors, the HER2 tumor marker testing market provides essential breast cancer companion diagnostics for targeted therapy guidance (Herceptin, Perjeta, Enhertu). IHC remains largest segment (initial screening, semi-quantitative), FISH definitive for 2+ cases, SISH fastest-growing (brightfield convenience, no fluorescence). The paradigm shift to “HER2-low” (IHC 1+) has expanded addressable testing population from 15% to 60% of metastatic breast cancer patients, driving significant volume growth. North America leads, Asia-Pacific fastest-growing. The full QYResearch report provides country-level consumption data by testing method and end-user, 12 supplier capability assessments (including IHC/FISH automation and HER2-low algorithm validation), and a 10-year innovation roadmap for HER2 tumor marker testing with extracellular vesicle (EV)-based liquid biopsy (plasma HER2 detection) and multiplex immunofluorescence AI scoring for combined HER2/ER/PR/PD-L1 in single slide.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
